Latest Regulatory Approval News

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Ramsay Health Care’s half-year results reveal a dramatic net profit rebound, driven by prior year impairments and solid growth in Australia and Europe. The company also announced a strategic acquisition and a proposed share distribution.

Autosports Group is making a strategic leap into South Australia by acquiring Solitaire Automotive Group, a luxury dealership powerhouse representing 10 premium brands. This $50 million deal is set to reshape the region’s luxury automotive retail landscape.

Eden Innovations is investing in new R&D equipment to enhance its carbon nanotube concrete technology, targeting the booming AI data centre market with improved heat dissipation and electromagnetic shielding.

Black Cat Syndicate has begun processing ore from its Fingals and Majestic mines through the Lakewood Mill and approved a $20 million expansion to boost capacity by 25%, aiming to lower costs and enhance cash flow.

Australia’s ANSTO has independently confirmed that Lindian Resources’ Kangankunde monazite concentrate is exempt from radioactive transport classification, simplifying export logistics and lowering downstream costs.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Caravel Minerals confirms its Definitive Feasibility Study for the Caravel Copper Project remains on track for mid-2026, while regulatory water investigations push the Final Investment Decision to late 2027. Meanwhile, strategic talks with Adani advance steadily.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.